text:
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.
Osteosarcoma and malignant fibrous histiocytoma (MFH) of the bone are diseases in which malignant (cancer) cells form in bone.
Osteosarcoma usually starts in osteoblasts, which are a type of bone cell that becomes new bone tissue. Osteosarcoma is most common in teenagers. It commonly forms in the ends of the long bones of the body, which include bones of the arms and legs. In children and teenagers, it often forms in the bones near the knee. Rarely, osteosarcoma may be found in soft tissue or organs in the chest or abdomen.
Osteosarcoma is the most common type of bone cancer. Malignant fibrous histiocytoma (MFH) of bone is a rare tumor of the bone. It is treated like osteosarcoma.
Ewing sarcoma is another kind of bone cancer, but it is not covered in this summary. See the PDQ summary on Ewing Sarcoma Family of Tumors for more information.
Having past treatment with radiation can increase the risk of osteosarcoma.
Anything that increases your risk of getting a disease is called a risk factor. Having a risk factor does not mean that you will get cancer; not having risk factors doesn't mean that you will not get cancer. People who think they may be at risk should discuss this with their doctor. Risk factors for osteosarcoma include the following:
Possible signs of osteosarcoma and MFH include pain and swelling over a bone or a bony part of the body.
These and other symptoms may be caused by osteosarcoma or MFH. Other conditions may cause the same symptoms. A doctor should be consulted if any of the following problems occur:
Imaging tests are used to detect (find) osteosarcoma and MFH.
Imaging tests are done before the biopsy. The following tests and procedures may be used:
A biopsy is done to diagnose osteosarcoma.
Cells and tissues are removed during a biopsy so they can be viewed under a microscope by a pathologist to check for signs of cancer. It is important that the biopsy be done by a surgeon who is an expert in treating cancer of the bone. It is best if that surgeon is also the one who removes the tumor. The biopsy and the surgery to remove the tumor are planned together. The way the biopsy is done affects which type of surgery can be done later.
The type of biopsy that is done will be based on the size of the tumor and where it is in the body. There are three types of biopsy that may be used:
The following tests may be done on the tissue that is removed:
Certain factors affect prognosis (chance of recovery) and treatment options.
The prognosis (chance of recovery) is affected by certain factors before and after treatment.
The prognosis of untreated osteosarcoma and MFH depends on the following:
After osteosarcoma or MFH is treated, prognosis also depends on the following:
Treatment options for osteosarcoma and MFH depend on the following:
After osteosarcoma or malignant fibrous histiocytoma (MFH) has been diagnosed, tests are done to find out if cancer cells have spread to other parts of the body.
The process used to find out if cancer has spread to other parts of the body is called staging. For osteosarcoma and malignant fibrous histiocytoma (MFH), most patients are grouped according to whether cancer is found in only one part of the body or has spread. The following tests and procedures may be used:
There are three ways that cancer spreads in the body.
The three ways that cancer spreads in the body are:
When cancer cells break away from the primary (original) tumor and travel through the lymph or blood to other places in the body, another (secondary) tumor may form. This process is called metastasis. The secondary (metastatic) tumor is the same type of cancer as the primary tumor. For example, if bone cancer spreads to the lung, the cancer cells in the lung are actually bone cancer cells. The disease is metastatic bone cancer, not lung cancer.
Osteosarcoma and MFH are described as either localized or metastatic.
Recurrent osteosarcoma and malignant fibrous histiocytoma (MFH) of bone are cancers that have recurred (come back) after being treated. The cancer may come back in the bone or in other parts of the body. Osteosarcoma and MFH most often recur in the lung, bone, or both. When osteosarcoma recurs, it is usually within 18 months after treatment is completed.
There are different types of treatment for patients with osteosarcoma or malignant fibrous histiocytoma (MFH) of bone.
Different types of treatment are available for children with osteosarcoma or malignant fibrous histiocytoma (MFH) of bone. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment.
Because cancer in children is rare, taking part in a clinical trial should be considered. Some clinical trials are open only to patients who have not started treatment.
Children with osteosarcoma or MFH should have their treatment planned by a team of health care providers with expertise in treating cancer in children.
Treatment will be overseen by a pediatric oncologist, a doctor who specializes in treating children with cancer. The pediatric oncologist works with other pediatric health care providers who are experts in treating osteosarcoma and MFH and who specialize in certain areas of medicine. These may include the following specialists:
Some cancer treatments cause side effects months or years after treatment has ended.
Side effects from cancer treatment that begin during or after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include the following:
Some late effects may be treated or controlled. It is important to talk with your child's doctors about the effects cancer treatment can have on your child. (See the PDQ summary on Late Effects of Treatment for Childhood Cancer for more information).
Four types of standard treatment are used:
Surgery to remove the entire tumor will be done when possible. Chemotherapy may be given before surgery to make the tumor smaller. This is called neoadjuvant chemotherapy. Chemotherapy is given so less bone tissue needs to be removed and there are fewer problems after surgery.
The following types of surgery may be done:
Studies have shown that survival is the same whether the first surgery done is a limb-sparing surgery or an amputation.
Even if the doctor removes all the cancer that can be seen at the time of the surgery, patients are also given chemotherapy after surgery to kill any cancer cells that are left in the area where the tumor was removed or that have spread to other parts of the body. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). Combination chemotherapy is the use of more than one anticancer drug. The way the chemotherapy is given depends on the type and stage of the cancer being treated.
In the treatment of osteosarcoma and malignant fibrous histiocytosis of bone, chemotherapy is usually given before and after surgery to remove the primary tumor.
See Drugs Approved for Bone Cancer for more information.
Radiation therapy
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy. External radiation therapy uses a machine outside the body to send radiation toward the cancer. Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer. The way the radiation therapy is given depends on the type and stage of the cancer being treated.
Osteosarcoma and MFH cells are not killed easily by radiation therapy. It may be used when a small amount of cancer is left after surgery or used together with other treatments.
Samarium is a radioactive drug that targets areas where bone cells are growing, such as tumor cells in bone. It helps relieve pain caused by cancer in the bone and it also kills blood cells in the bone marrow. It also is used to treat osteosarcoma that has come back after treatment in a different bone.
Treatment with samarium may be followed by stem cell transplant. Before treatment with samarium, stem cells (immature blood cells) are removed from the blood or bone marrow of the patient and are frozen and stored. After treatment with samarium is complete, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.
New types of treatment are being tested in clinical trials.
This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about ongoing clinical trials is available from the NCI Web site.
Targeted therapy
Targeted therapy is a treatment that uses drugs or other substances to find and attack specific cancer cells without harming normal cells.
One kind of targeted therapy being studied to treat recurrent osteosarcoma is a drug that stops cells from dividing and prevents the growth of new blood vessels that tumors need to grow. This drug is a type of antiangiogenesis agent.
Viral therapy is another type of targeted therapy being studied to treat recurrent osteosarcoma. It uses a virus that has been changed in the laboratory to find and destroy cancer cells without harming healthy cells.
Patients may want to think about taking part in a clinical trial.
For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.
Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.
Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
Patients can enter clinical trials before, during, or after starting their cancer treatment.
Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.
Clinical trials are taking place in many parts of the country. See the Treatment Options section that follows for links to current treatment clinical trials. These have been retrieved from NCI's listing of clinical trials.
Follow-up tests may be needed.
Some of the tests that were done to diagnose the cancer or to find out the stage of the cancer may be repeated. Some tests will be repeated in order to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests. This is sometimes called re-staging.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back). These tests are sometimes called follow-up tests or check-ups.
A link to a list of current clinical trials is included for each treatment section. For some types or stages of cancer, there may not be any trials listed. Check with your doctor for clinical trials that are not listed here but may be right for you.
Localized Osteosarcoma and Malignant Fibrous Histiocytoma of Bone
Treatment may include the following:
Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with localized osteosarcoma and localized childhood malignant fibrous histiocytoma of bone. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.
Metastatic Osteosarcoma and Malignant Fibrous Histiocytoma of Bone
Lung Metastasis
When osteosarcoma or malignant fibrous histiocytoma (MFH) spreads, it usually spreads to the lung. Treatment of osteosarcoma and MFH with lung metastasis may include the following:
Bone Metastasis or Bone with Lung Metastasis
Osteosarcoma and malignant fibrous histiocytoma may spread to a distant bone and/or the lung. Treatment may include the following:
Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with metastatic osteosarcoma and metastatic childhood malignant fibrous histiocytoma of bone. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.
Recurrent Osteosarcoma and Malignant Fibrous Histiocytoma of Bone
Treatment of recurrent osteosarcoma and malignant fibrous histiocytoma of bone may include the following:
Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with recurrent osteosarcoma and recurrent childhood malignant fibrous histiocytoma of bone. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.
For more information from the National Cancer Institute about osteosarcoma and malignant fibrous histiocytoma of bone, see the following:
For more childhood cancer information and other general cancer resources from the National Cancer Institute, see the following:
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Changes were made to this summary to match those made to the health professional version.
Call 1-800-4-CANCER
For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.
Chat online
The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
Write to us
For more information from the NCI, please write to this address:
Search the NCI Web site
The NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families. For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.
There are also many other places to get materials and information about cancer treatment and services. Hospitals in your area may have information about local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.
Find Publications
The NCI has booklets and other materials for patients, health professionals, and the public. These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials. Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities. NCI materials on these and other topics may be ordered online or printed directly from the NCI Publications Locator. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).
PDQ is a comprehensive cancer database available on NCI's Web site.
PDQ is the National Cancer Institute's (NCI's) comprehensive cancer information database. Most of the information contained in PDQ is available online at NCI's Web site. PDQ is provided as a service of the NCI. The NCI is part of the National Institutes of Health, the federal government's focal point for biomedical research.
PDQ contains cancer information summaries.
The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries are available in two versions. The health professional versions provide detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions provide current and accurate cancer information.
The PDQ cancer information summaries are developed by cancer experts and reviewed regularly.
Editorial Boards made up of experts in oncology and related specialties are responsible for writing and maintaining the cancer information summaries. The summaries are reviewed regularly and changes are made as new information becomes available. The date on each summary ("Date Last Modified") indicates the time of the most recent change.
PDQ also contains information on clinical trials.
A clinical trial is a study to answer a scientific question, such as whether one treatment is better than another. Trials are based on past studies and what has been learned in the laboratory. Each trial answers certain scientific questions in order to find new and better ways to help cancer patients. During treatment clinical trials, information is collected about the effects of a new treatment and how well it works. If a clinical trial shows that a new treatment is better than one currently being used, the new treatment may become "standard." In the United States, about two-thirds of children with cancer are treated in a clinical trial at some point in their illness.
Listings of clinical trials are included in PDQ and are available online at NCI's Web site. Descriptions of the trials are available in health professional and patient versions. For additional help in locating a childhood cancer clinical trial, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
The PDQ database contains listings of groups specializing in clinical trials.
The Children's Oncology Group (COG) is the major group that organizes clinical trials for childhood cancers in the United States. Information about contacting COG is available on the NCI Web site or from the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
Last Revised: 2012-03-08
If you want to know more about cancer and how it is treated, or if you wish to know about clinical trials for your type of cancer, you can call the NCI's Cancer Information Service at 1-800-422-6237, toll free. A trained information specialist can talk with you and answer your questions.
This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.
To learn more visit Healthwise.org
© 1995-2012 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.


text:
, 6pm – Tickets are $5 Door
Come on down to our weekly acoustic bluegrass pickin' party and show us what you've got! Eat, drink, play and be merry!
The best bluegrass jam in Atlanta starts at 6pm, then Culliton, Dean & Hall take the stage at 8pm! From traditional bluegrass, newgrass, and swing, to original compositions, Culliton, Dean & Hall feature powerful instrumentals with inspired vocals.

subset: commoncrawl


text:
Electronics Production | October 26, 2009
HDD in volume production negotiations with Kitron and Flextronics
The Norway-based company High Density Devices (HDD) is currently negotiating possible production deals with EMS-providers Kitron and Flextronics.
HDD believes that Data Encryption will soon be a billion dollar industry. With fresh capital and a new management, the company is planning to commercialise its products for the mass market. EMS-providers Kitron and Flextronics are both named as possible manufacturing partners for the volume production of HDD's products. High Density Devices is also currently in discussions with potential licence promoters.
Another battery production facility to be built in Germany A new production facility for electric vehicle power solution provider, Microvast GmbH, is to be constructed by industrial developer, Panattoni Europe.
BMW is betting billions on e-mobility – awards massive battery contracts The BMW Group is forging ahead with electromobility and deepening its existing business relationships with battery cell manufacturers CATL (Contemporary Amperex Technology Co. Limited) and Samsung SDI.
UMS Skeldar gears up production volumes with Scanfil Close on the heels of German Navy and Royal Canadian Navy contracts UMS SKELDAR gears up production volumes as part of world navy strategy roll out.
Demand for preemptive 3Q19 DRAM shipment rises According to DRAMeXchange, demand-side inventory in 2H19 has returned to relatively healthy levels. Furthermore, some vendors pulled their quarterly product shipment forward in an effort to avoid potential negative impacts from Trump's impending tariffs.
Sponsored content by Z ElektronikaZ Elektronika opens new factory in Pécs To keep up with rapid growth of the company, on the 13th September Z Elektronika celebrated the grand opening of its new electronic design and manufacturing facility close to the highway in Pécs, Hungary, which adds new features and production site to its nearby location.
HANZA gets AS9100 certificate to supply aerospace industry Swedish manufacturing strategist, HANZA, says that its machining facility in Årjäng, Sweden, received its AS9100 certification, the standard that will allow HANZA to manufacture products for the aviation, space and defense companies.
NOTE continues to expand within medtech One of EMS provider NOTE's Swedish manufacturing plants has received a first order of SEK 25 million (EUR 2.34 million) from a Swedish customer within the medtech segment. Delivery is scheduled for 2020.
Marvell layoffs in VT, NC and CA Days after the close of the acquisition of Avera Semiconductor on November 5, Marvell Semi filed a WARN notice with the State of Vermont, ahead of 78 permanent layoffs at its Essex Junction facility.
U.S. DoC extends Huawei license The United States Dept. of Commerce, through its Bureau of Industry and Security (BIS), has announced a 90-day extension of the temporary general license (TGL) to Huawei and certain non-affiliates.
Sponsored content by EsemdaContract manufacturer Esemda opens new facility in Vilnius and expands EMS The new facility has been built with reserved space for future expansions. As Esemda constantly grows, it is of great importance to be able to rapidly increase production capacity in large volumes.
Apple: Shovels up in Austin As part of its expansion plan in Texas, Apple has announced the beginning of construction at its new campus in North Austin.
PARPRO makes NA capex investments Southern California-based PARPRO has made capital equipment investments scheduled to be operational this quarter at the company's Mexico and California facilities.
Indium Corporation is ready for 2020 Chris Nash from Indium Corporation reviews 2019 - in many ways, a strange year. However, even with the geopolitical issues that the year has offered, Indium has done a good job staying on top of things.
Schmoll Maschinen GmbH settles for a record year Schmoll's soaring results for 2019 is tied to the high level of globally deployed machines, where Asia takes the lead.
Arch Systems partners with Flex for manufacturing data transformation Arch Systems, a provider of a machine-data-sensing platform, has entered into an agreement with global manufacturer Flex to supply real-time access to and analysis of manufacturing data at its facilitie
ZF and Wolong Electric form JV for electric motors ZF Friedrichshafen and China's Wolong Electric Group are stepping up their existing cooperation. The two companies have signed an agreement to establish a joint venture that will produce components and electric motors for automotive applications.
Cicor on its venture into printed electronics In the first quarter of 2019, Swiss EMS provider, Cicor, opened a technology center for printed electronics at the Bronschhofen site in Switzerland - quite the investment and a completely new territory for the company. Evertiq had the opportunity to talk to Karl-Heinz Fritz, VP of Technology, about the strategy behind this.
TT Electronics steps up its US presence – acquires Excelitas unit TT Electronics has struck a deal to acquire a US based business that designs and manufactures power electronics for defence and aerospace markets, enhancing its ability to engineer complete power converters.
ABB partners with Exeger to speed up transition to clean energy ABB has entered into a new partnership with Sweden's Exeger Operations AB. The partnership will enable Exeger to enhance the production quality its photovoltaic material at the company's Stockholm factory and also develop automation solutions for its new fully automated factory which will begin construction in the near future.
Rehm Thermal Systems intros 3-in-1 reflow solution Michael Hanke from Rehm Thermal Systems shows off the results of the company's development work.
Intel to reclaim No.1 semiconductor supplier ranking in 2019 IC Insights says that only three among the top-15 semiconductor suppliers are forecasted to show growth this year.
Veoneer joins Autonomous Vehicle Computing Consortium Veoneer has joined the Autonomous Vehicle Computing Consortium (AVCC) to speed autonomous driving vehicle development.
Ongoing trade issues have opened up Chinese market for Viscom According to Carsten Salewski, Chinas move towards more independence has resulted in more customers from the region; especially within the automotive sector.
Don't forget about human inclusion in industry 4.0 Michael Ford from Aegis Software is reminding the industry in the midst of connectivity that our most powerful asset is still the human employee.
East West Manufacturing acquires Adcotron EMS East West Manufacturing has acquired Adcotron EMS, a provider of specialized electronics manufacturing services, including advanced printed circuit board assemblies, box-build assemblies, testing, and new product introduction services.Load more news
Related news


text:
It's been a while. Again my deepest apologies, I'm currently working and interning.
I was working at a screen printing place in Bermondsey 2 weeks ago, and at the end of my placement I got to print several projects I had in mind. This is one of the prints I hand sketched for my Islamic Project, printed onto a basic mens t-shirt.
What I'm wearing:
Tshirt - My own
Black velvet dress (worn under) - Charity Shop
Odd Everlast Socks - JD's
Sandals - New Look
Cat Sunglasses - Camden Markets
Also couldn't help but realise I've just moved from 2k to 4k on Lookbook, I was really surprised when I logged on after 2 months. So thank you so much for those who keep looking at my posts and for following <3 Even though I've been Idling when it comes to blogging.
Thank you so much again


text:
Students requiring special accommodation should contact the Office of Residential Life as early as possible. If you have a special medical, psychological or learning need, the Office of Residential Life will make every effort to provide the most appropriate, on-campus, housing assignment for you.
Barrier-free rooms are available for students with impaired mobility. Some rooms are equipped with visual fire alarms to serve the hearing impaired. Some additional rooms are available to help mitigate allergy concerns.
If you have a special need, please complete and submit a Special Housing Accommodation Request form as soon as is possible. Your request will need to be accompanied by appropriate supporting documentation (e.g., medical records).
Your request will be reviewed by the Office of Student Accessibility Services in consultation with Health Services, the Counseling Center, and other appropriate college offices. The goal of this review is to provide an on-campus housing accommodation that best meets your need. The accommodation option(s) will be limited to those currently available on campus.


text:
Top 10 Hunger Games Moments We Can't Wait to See on The Big Screen
Watch out wizarding kids and blood-sucking vamps--there's a new blockbuster in town. Hunger Games hits theaters at midnight tonight and we could not be more excited--as devote fans of the mega-hit book series, we're eager to see which of our favorite moments and most beloved characters make it into the big-screen adaptation. We've rounded up the top ten moments we can't wait to see:
Photo Credit: MURRAY CLOSE/LIONSGATE
The Reaping
No other scene in the book describes the character of Katniss more perfectly than the gut-wrenching moment when she bravely accepts a place in the Hunger Game instead of her younger sister, Prim. From what we've gleaned from previews (yes, we had to peek) leady-lady Jennifer Lawrence absolutely nails the role of Katniss--and the desperation of this scene in particular.
The Capitol
In Suzanne Collin's best-selling book series, the Capitol is the epitome of over-indulgence. Its residents are glamorous, gluttonous and over-the-top, and we can't wait to see how the utopian society will translate in film.
The Opening Ceremony
The Opening Ceremony is arguably one of the most important scenes in the first installment of the Hunger Games trilogy. At the hands of her stylist Cinna (played brilliantly by Lenny Kravitz) Katniss is transformed into "The Girl on Fire," setting the foundation for an uprising that transcends all three novels. We can wait to see how all the Tributes costumes are depicted.
Photo Credit: MURRAY CLOSE/LIONSGATE
The Arena
The Arena is where the core of the story takes place--a dangerous, mysterious place that challenges the Tributes with every step. From the tracker jackers to the mutants, we're left with reserved anticipation for how the Games will play out.
The Moment When Katniss Shoots the Pig
Plain and simple, this is one of the most girl-power moments in the whole story. Katniss is an exemplary heroine for many reasons, but the moment she decides she isn't going to play into the capitols hands and shoots an arrow straight into the mouth of a pig almost made us want to stand up and cheer.
The Countdown
If you caught one of the million previews that has graced television networks these past few weeks, chances are you've seen our next moment--the countdown to the Arena begins and Katniss and Peeta are lifted up via-glass tubes. The few minutes of chaos and madness that follow are sure to be heart stopping in theatres.
The Make-Up
From Effie's pink skin, to Cinna's crazy outfits and Katniss' trademark braid, we can't wait to see all the hair and makeup magic that goes into a production of this magnitude. When the novel's characters are already describe as fantastical, you know the Hollywood version will pull out all the stops.
Photo Credit: MURRAY CLOSE/LIONSGATE
The Berry Threat
Who could forget the moment when Katniss and Peeta go all Romeo and Juliet on the Capitol and threaten to eat poison berries if they're going to be forced to kill one another? Katniss' act of defiance is enough to ignite an uprising against the Capitol and is the force that drives the final two novels.
The Death of Rue
Perhaps anticipating isn't the right word for this scene--however, the heartbreaking moment where Katniss' close ally (and the youngest Tribute) dies is extremely touching. We're looking forward to how Lawrence brings this poignant scene to life.
The Cave
Everyone loves a little romance and us Hunger Games fans are no exception. We rooted for Peeta all the way through the first novel and this moment was a sweet glimpse into their budding romance amongst the horrors of the Arena. Here's to hoping Lawrence and Josh Hutcherson have the killer chemistry on screen needed to pull off one of our favorite moments.
--Alyssa Longobucco
More from SELF:
Hungry for the Hunger Games? Check Out These Inspired Meals!
Get in Tribute Shape With the Hunger Games Workout
Slim Down and Shape Up With SELF's Drop 10 Diet
For daily healthy eating tips follow SELF on Facebook and Twitter.
Get SELF on your iPad and Kindle Fire!


text:
Click here before shopping AMAZON! xjalk.com will get a few cents from every purchase!
Ironman4x4fab.com "Andy" showing you what he's working on!
Use this control to limit the display of threads to those newer than the specified time frame.
Allows you to choose the data by which the thread list will be sorted.
Order threads in...
Note: when sorting by date, 'descending order' will show the newest results first.
Forum Rules


text:
Tagged: new york mets
Rod Gaspar
Eddie Murray was choking…
9-24-08 Autographs – Eddie Murray
Tustin, California
I got a tip earlier today that Hall of Famer Eddie Murray was going to be signing autographs at a Restaurant. I was a little surprised. Murray is a complicating person. He doesn't enjoy signing autographs. I've met him a couple of times and he's always in a bad mood. Well the times I have met him. Back in 2006 the Dodgers held a caravan at the ESPN Zone in Anaheim and several Dodgers were going to be signing. Including Murray. I gave him a ball and he signed it with a sharpie !! I was upset. It was my mistake for not noticing what Murray was doing. Check out the pix below from 2 years ago. Murray holding a blue sharpie in his hand. Steve Garvey by his side saying "Oh Steady Eddie, relax…you need a woman" and the female bodyguard yelling "Get that camera out of here!" As you can see, not a good picture. Too many people in the picture. My purpose for today was to get him to sign a ball with a regular pen and get another picture. Will mission be accomplished ? Keep reading…
If you don't know, a ball signed by a sharpie is worthless. It will bleed into the ball and the signature will fade in time. A ball has to be signed by a regular pen. A couple of people have told me that Murray does that in purpose. Basically so you won't sell the item. Of course, I'm not a seller or a dealer. I just collect autographs as a hobby. But Murray doesn't care. Anyways, since I got this tip today, I didn't have time to purchase items for him to sign. I didn't have nothing. I'm sure I could of found something at home but I didn't have time to check. Luckily I was able to purchase a ball from someone (The same guy that gave me this tip, thanks dude!) I arrived a little before 6pm. He was scheduled to appear at Beach Pit BBQ. I entered the restaurant and noticed there wasn't alot of people. Someone approached me and asked me "Are you the guy that has a blog?" lol I said "yeah that's me" His name is Ryan and he told me he reads my blog all the time. Thanks Ryan ! Then I asked a employee if Murray was coming. He told me that Murray will be coming and signing autographs for free. I asked if I had to purchase a meal and he said no. That's cool by me. But then I noticed a couple of people eating and it looked good. Since I'm always hungry, I told my Wife I was going to eat BBQ Chicken. We ordered the food and sat down. Then I will give you a Andre Ethier type review… lol I got this…
The BBQ Chicken was pretty good. But in no way does it compare to Lucille's BBQ ! You want bbq Chicken or ribs ? Go to Lucille's. Enough of my short food review 🙂 When I was about to finish my food, I noticed that Murray entered the Restaurant. He talked to a couple of people and then sat down. A couple of minutes later, he started signing. Fans were already getting in line so I decided to wait until it gets shorter. Not alot of people were there. I think there was less than 30 fans in line. I finished my food and got in line. I asked a couple of fans who already got the autograph if he was in a good or bad mood. Some said he was in a bad mood and others said he looked alright. One guy told me he gave him 3 items to sign but he only signed 2 and if I could get him the other item signed for him. At first I said no because I wanted to get a picture with him and didn't want to upset him. But then I remembered I could give it to my Wife since she didn't have anything to get signed. So that's what I did. I don't remember the guy's name but you owe me. lol Then right after he gave me the item, another fan asked me if I could get him a item signed. This time I said no. Sorry dude. So it was my turn to meet him and I gave him the ball with MY PEN ! I didn't want the same mistake to happen. He grabbed my ball and looked at me….and looked….and looked some more….and a little more….While I was thinking "What is he looking at?" Then I noticed his eyes looking at my hat. Oh fudge, I forgot. I was wearing a Dodgers hat ! I put the hat on purpose but I forgot at that moment that I had it on. It wasn't a regular Dodger hat. It was the hat that had the Stars and Stripes on it. To see it, click here. The hat that was worn by the players during the 4th of July weekend and on September 11 🙂 I told him "Yeah I'm a big Dodgers fan" and he coughed…and coughed more. "Dodgers treated you bad, huh?" I said. He coughed more. At this moment I thought he was going to need some medical attention. I thought he was choking. Maybe he needed CPR ? I don't know. I mean I know he got fired by the Dodgers last year during the All-Star break but what's the problem ? Then he said "Yeah…" Coughed some more. Then he started signing my ball with my pen and this is a picture that my Wife took when I tell him "Yeah brother, that's right, you better not sign it with a sharpie!"
I asked for a picture and believe it or not he obliged. You have to remember that he also played for the Anaheim Angels and I was in Angels territory (Tustin) so he might have been surprised that a Dodger fan showed up and it seems he is still upset at the Dodgers. Whatever. I got a ball and everything went well. I mean it could of been better. If I was prepared and had more items for him to sign. But in a short notice, it's all good. Thanks Eddie ! Pix of Eddie telling me "Viva los Dodgers"
Eddie Murray autographed ball on the sweet spot 🙂
BTW, FYI Eddie choking (or coughing anger) True story. Me telling Eddie better not sign it with a sharpie, not a true story 🙂 Don't want to get sued with false accusations 🙂 lol


text:
Taylor Swift & John Mayer Dine Separately at Chateau Marmont on the Same Night!
Taylor Swift sits in the back seat of a car while leaving Chateau Marmont after grabbing dinner on Wednesday evening (August 20) in West Hollywood, Calif.
That same night, the 24-year-old singer's ex-boyfriend John Mayer was seen exiting the premises in a different car. Our sources believe they didn't sit together, but funny coincidence that they wound up there on the same night!
PHOTOS: Check out the latest pics of Taylor Swift
"Taylor was with Lily Aldridge and never saw Mr. Mayer at Chateau Marmont," Tay's rep told E! News.
Taylor and John famously dated back in late 2009 through early 2010, which inspired her song "Dear John," off her Speak Now record. John then reportedly wrote his 2013 track "Paper Doll" about their relationship.
In case you missed it, be sure to check out Taylor's brand new music video for her latest single "Shake It Off"!
Posted to: John Mayer, Taylor Swift


text:
Joseph (Petrovykh) of Petrograd
Metropolitan Joseph (Petrovykh, 1870?-1938) was a vicar of Petrograd and was transferred in 1926 to Odessa. He refused to move from his see and was martyred by the communists after a series of imprisonments for not recognizing the declaration of Metropolitan Sergius as valid. He was widely regarded as the most vocal leader of the Catacomb Church in Russia Her formative years. He was glorified as a New Martyr by the Russian Orthodox Church Outside Russia, but his glorification has not been recognized by the Patriarchate of Russia.


text:
Washington College (Public Announcement)posted to: Washington College News Page
CHESTERTOWN, MD—Washington College has named Satyajit Dattagupta, an admissions executive at the University of Rochester with a strong background in computer science and data analysis, as its new Vice President for Enrollment Management. He will succeed Kevin Coveney, who is stepping down July 1 after 30 successful years of growing enrollment at the College.
In making the announcement, Washington College president Mitchell B. Reiss said the Search Committee was especially impressed with Dattagupta's understanding of how cutting-edge technology can be used to promote the College and reach prospective students and their families. "It's clear from his past success that Satyajit brings tremendous energy, passion and intelligence to whatever challenge he tackles. He knows how to analyze data, build cohesive teams and create effective strategies. And he understands the new media world and how colleges need to adjust their thinking in a very competitive marketplace."
At the University of Rochester, Dattagupta serves as Executive Director of the Office of College Enrollment, leading a team of 14 employees in planning and executing communications, marketing and technology strategies for university admissions. In his more than two years as director, he has invested in areas such as process engineering, data-driven marketing and analysis, 3D modeling, social media and video. These innovations have helped Rochester create a 25 percent increase in applications over three years, with desired yields (accepted students who enroll) and a stronger freshman class profile.
"Washington College is gaining a tremendous professional in Satyajit," says Jonathan Burdick, the dean of admissions and financial aid at the University of Rochester. "I have known him for five years and have enjoyed our work together at Rochester. I couldn't be more proud of him, and I'm glad to see that in Washington College he has found a new leadership platform. I predict great opportunities and growth for everyone there in Chestertown in the years ahead."
Dattagupta's previous positions include two years at DePauw University as associate director of admission and coordinator of information technology, and two years as a project manager and web analyst for Minnesota State Colleges and Universities, the governing body for 31 schools operating in 47 communities.
A native of Mumbai, Maharashtra, India, Dattagupta earned both a bachelor's degree in computer science and a master's in business administration from Southwest Minnesota State University. He will move to Chestertown with his wife, Priyanka, this summer and officially starts his new job July 1.
"Enrollment management is a marriage of the science of numbers and the art of recruiting," he says. "And I am excited about applying my expertise and experience in both those areas at Washington College, building on what Kevin and his team have created."


text: Missoni's Slinky Fall – After last season's explosion of colors, the fall 2012 collection from Missoni muted the color palette and focused on form-fitting shapes for the new season. Designer Angela Missoni created cozy yet seductive knitwear in dreamy tones of sage green, camel, ash grey and burgundy. Accessories included thin belts above the waist, fur hats, latex gloves and boots with chunky heels. Of course, Missoni's signature prints were also put on full display with a mix and match of luxe winter layers.


text:
Game #51: Yankees at Blue Jays pregame
New York (21-28) at Toronto (23-27)
at 7:07 p.m. ET at the Rogers Centre
Today's lineups:
Johnny Damon, CF
Derek Jeter, SS
Hideki Matsui, LF
Alex Rodriguez, 3B
Jorge Posada, C
Jason Giambi, DH
Bobby Abreu, RF
Doug Mientikiewicz, 1B
Robinson Cano, 2B
PITCHING: LHP Andy Pettitte
Alex Rios, RF
Lyle Overbay, 1B
Vernon Wells, CF
Frank Thomas, DH
Aaron Hill, 2B
Jason Phillips, C
Royce Clayton, SS
Adam Lind, LF
John McDonald, 3B
PITCHING: RHP Shaun Marcum
NOTES: To clear room for RHP Brian Wolfe on the 40-man roster, Toronto transferred RHP Brandon League to the 60-day disabled list. This was simply a paperwork move, considering League has been on the DL since March 31. Even with placing him on the 60, he's eligible to come off the DL this week. League is beginning a rehab assignment with Class A Dunedin today. … 3B Troy Glaus, who has been bothered all year by a bone spur in his left heel, was a late scratch from Toronto's lineup. … RHP Victor Zambrano (right forearm) was scheduled to make a rehab start with Triple-A Syracuse on Tuesday night.
4 Comments
Well its official…well at least obvious if anything. Markum is definitely a number 3 starter. Hes proved himself the best he can. Maybe that can change with McGowan pitching well lately but Markum has been so consistent and getting better. A little weird mind you how they keep pulling him around 70-80 pitches. One thing that I cant understand is why Stairs was not in the rotation today. What the heck..Lind. I know he came through late today but other then that hes silent at the plate for quite a while.
1. Stairs is not in the rotation because the Jays are not desperate enough as to let their (surprisingly succesfull) aging 4th outfielder pitch 5-6 innings.
2. Given the fact that the Jays got hurt so badly and resorted to having a very young rotation, Giving Lind some valuable playing time is key here. While Stairs have made some crucial clutch moments happen, he is a 4th outfielder close to retirement while Lind is being groomed to be the future of the club (not alone, but they expect him to be a star)
3. Doc – AJ – Marcum – McGowan is a solid rotation … having guys like Litsch and Ohka fill in for Chacin is not such a terrible 5th spot solution.
4. Despite Ohka's QS I believe they are opting to let Litsch stick around for the reasons I have mentioned regarding Lind… Ohka is a stop-gap solution who will give a .500 season > 4.5 ERA and will go on to make 8 million a year a la batista/ weaver… while Litsch is an exciting young arm with a competitive attitude who is expected to make at least a reliable 3-5 spot major leaguer who will be under rent control for a few years
It sure was nice to see the small ball work. It isn't always as exciting to watch as the home runs, and the big innings but it can be. Fundamentals still do work.
Sorry I meant line up or batting order if you like for the comment on Stairs.


text:
Life Science: Session 7
What is a community?
Communities are populations of organisms that interact with each other. As with each level of organization in the living world, certain phenomena in a community act to shape and sustain it. The interactions among different populations are what hold a community together. Some interactions involve the provision of habitat. A good example is a tree that houses birds, insects, and other creatures. Other vital interactions involve reproduction, such as plants that are pollinated by insects. Symbiotic interactions, such as the relationship between algae and fungi in lichens, are also important.
Without a doubt, the most important interactions in a community involve energy flow — the transfer of energy along food chains from one organism to the next. Without this flow of energy, individual organisms cannot survive and the community collapses.
How does energy flow in a community?
In any community, there are the producers, consumers, and decomposers. Producers include plants and some protists, bacteria, and archaea. These individuals take in energy in an inorganic (i.e., nonliving) form, such as light, and change it into food, which is an organic form of energy. This energy is used or stored in the organic molecules that compose a producer's body.
Consumers are organisms that can't make their own food. The most familiar consumers to us are animals. They represent the "typical" consumer in that they ingest food to obtain energy. Some animal consumers eat plants, some eat other animals, and some eat a variety of food sources. Certain protists, like the amoeba, are also consumers.
A special group of consumers is the decomposers. Like other consumers, they can't make their own food. They differ from other consumers because they obtain their energy by decomposing the bodies of dead things. They secrete digestive chemicals onto their food and break large molecules into smaller ones that they then absorb. The most important decomposers in most communities are the fungi and the bacteria. Some protists and archaea are also decomposers.
|prev: energy and life
|next: photosynthesis


text:
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.
Newcastle disease virus (NDV) is a virus that causes a deadly infection in many kinds of birds. In humans, NDV causes mild flu-like symptoms or conjunctivitis (an infection of the eye that is also called pink eye) and/or laryngitis (an irritation and swelling of the voice box and the area around it).
Like other viruses, NDV infects cells (called host cells) and then uses those cells to replicate (make copies of) itself. Researchers are interested in NDV because it replicates itself more quickly in human cancer cells than in most normal human cells and it can kill the host cells. For these reasons, the virus is being studied as a treatment for cancer.
The first report that NDV may be useful as a cancer treatment was published in 1964. For 20 years before this report, NDV was used in a vaccine to prevent Newcastle disease in birds. During that time, it was learned that NDV caused only minor illness in humans. The mild side effects caused by NDV in humans and its ability to replicate up to 10,000 times faster in human cancer cells than in most normal human cells, led complementary and alternative medicine researchers to look more closely at NDV as a possible cancer treatment. NDV is now being studied by conventional medicine researchers also.
There are many strains of NDV, and they may be either lytic or nonlytic for human cells. Lytic strains kill the infected cell by damaging its outer membrane (layer of tissue). Nonlytic strains kill by blocking the basic processes a cell needs to live. Lytic strains of NDV have been studied in humans because they can kill cancer cells directly, but both lytic and nonlytic strains have been used to make vaccines to help the immune system fight cancer.
The way NDV is given depends on how the virus is used to target cancer cells. It may be used to directly infect the patient with NDV or to make cancer vaccines. Cancer vaccines made with NDV may improve the body's natural immune response to cancer, causing it to attack and kill more cancer cells than it would if the NDV were not present. Researchers are studying 3 ways of using NDV as a possible cancer treatment:
NDV can be injected directly into the tumor, a muscle, or a vein (intravenous injection), or into the colon. The virus can also be inhaled. As explained in Question 1, NDV infects cells and then replicates itself, creating more copies of the virus that can then infect cells throughout the body. This process targets and kills cancer cells by damaging the cells' outer membranes.
Oncolysate vaccines are made using pieces of cancer cell membranes infected with NDV. Oncolysate-based vaccines are injected under or into the skin.
Whole-cell vaccines are made using whole tumor cells infected with NDV. The tumor cells used in the vaccine are changed in the laboratory so that they cannot multiply or infect the patient. Whole-cell vaccines with NDV are given only by injection under the skin.
A number of preclinical studies have been done with NDV. Research in a laboratory or using animals is done to find out if a drug, procedure, or treatment is likely to be useful in humans. These preclinical studies are done before any testing in humans is begun. The following has been learned from preclinical studies:
A few of these studies used human cells, but most used animal cells. Based on these and other laboratory findings, clinical trials (research studies with people) using NDV were begun.
Clinical trials of NDV have been done but have not proven that NDV is effective as a cancer treatment. Some of the trials reported positive results and some did not. Most of the studies enrolled only small numbers of patients who also received standard treatments. None of the trials published in English were randomized and few were controlled. Randomized clinical trials give the highest level of evidence. In randomized trials, volunteers are assigned randomly (by chance) to one of 2 or more groups that compare different factors related to the treatment. In a controlled clinical trial, one group (called the control group) does not receive the new treatment being studied. The control group is then compared to the groups that receive the new treatment, to see if the new treatment works. Randomized controlled trials, enrolling larger numbers of people, are needed to confirm the results of studies done so far on the use of NDV to treat cancer.
Clinical trials studying the use of NDV as a cancer treatment have been done in the United States, Canada, China, Germany, and Hungary. Below are brief descriptions of these studies.
Studies Using Oncolysate Vaccines
Four clinical trials in the United States studied the use of NDV oncolysates in patients with metastatic melanoma. Three of these studies, a phase I clinical trial and 2 phase II clinical trials, were by the same group of researchers. Some positive results were found in these studies. The fourth trial was led by different researchers and showed no benefit. The same type of NDV was used to make the vaccines in all 4 studies, but the 2 groups of researchers used different methods to make them. Results from these studies need to be confirmed by randomized controlled trials that enroll larger numbers of people.
Two other phase II trials of NDV oncolysates were done in Germany. One of the studies showed that people in the trial had longer disease-free survival when compared with published information on similar patients who were treated with surgery alone. Because these studies were not controlled and the patients received other treatments, it is not clear if it was the treatment with NDV oncolysates that caused the responses reported.
Studies Using Whole-cell Vaccines
Most of the published clinical studies of whole-cell vaccines with NDV have been done in Germany. The largest reported trial was in China. Most of these studies involved patients with colorectal cancer, breast cancer, ovarian cancer, renal cell (kidney) cancer, or malignant glioma. The same type of NDV was used to make the vaccines in all of the studies.
Some of these studies found improved disease-free survival or improved overall survival in patients treated with whole-cell vaccines. The lack of control groups and other weaknesses in study design and reporting made it unclear if benefits were caused by the whole-cell vaccine or by something else. Overall, the results showed that these vaccines may help the immune system kill more cancer cells during the vaccination program but may not provide long-term cancer immunity.
Studies Involving Infection with NDV (Including MTH-68)
Most research on the treatment of cancer by infecting patients with NDV has been done in Hungary, using the NDV strain MTH-68. The published findings include the following types of studies:
According to the researchers, the MTH-68 treatment was helpful for most of the patients in these studies. The number of patients in the studies was small, however, and the patients in the clinical trial were not randomly assigned. The patients also received other treatments. For these reasons, it is not known if the patients were helped by the MTH-68 or by something else.
In the United States, a phase I clinical trial tested PV701, another type of NDV. In this trial, 79 patients with advanced cancers that were not helped by conventional therapy were given PV701 by injection into a vein. Some patients had partial responses to the treatment, while others did not have any change in their condition. More studies are planned.
One major concern is that repeated injections of NDV may cause a person's immune system to form antibodies against the virus. These antibodies would prevent NDV from infecting and killing cancer cells. More research is needed to study this.
While most studies of NDV in cancer treatment have been small and without control groups, there have been enough promising results to call for continued research.
The side effects caused by NDV exposure have been mild to moderate. As noted in Question 1, NDV causes mild flu-like symptoms, conjunctivitis, and laryngitis in humans. Other side effects vary with how the virus is given.
Studies that combined treatment with NDV oncolysates or whole-cell vaccines with substances called cytokines reported flu-like symptoms, fever, and swelling. The side effects seen in these studies have been linked to the cytokine portion of the treatment.
The US Food and Drug Administration (FDA) has not approved Newcastle disease virus as a treatment for cancer.
Check NCI's list of cancer clinical trials for cancer CAM clinical trials on oncolytic Newcastle disease virus that are actively enrolling patients.
General information about clinical trials is available from the NCI Web site.
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Editorial changes were made to this summary.
Complementary and alternative medicine (CAM)—also referred to as integrative medicine—includes a broad range of healing philosophies, approaches, and therapies. A therapy is generally called complementary when it is used in addition to conventional treatments; it is often called alternative when it is used instead of conventional treatment. (Conventional treatments are those that are widely accepted and practiced by the mainstream medical community.) Depending on how they are used, some therapies can be considered either complementary or alternative. Complementary and alternative therapies are used in an effort to prevent illness, reduce stress, prevent or reduce side effects and symptoms, or control or cure disease.
Unlike conventional treatments for cancer, complementary and alternative therapies are often not covered by insurance companies. Patients should check with their insurance provider to find out about coverage for complementary and alternative therapies.
Cancer patients considering complementary and alternative therapies should discuss this decision with their doctor, nurse, or pharmacist as they would any therapeutic approach, because some complementary and alternative therapies may interfere with their standard treatment or may be harmful when used with conventional treatment.
It is important that the same rigorous scientific evaluation used to assess conventional approaches be used to evaluate CAM therapies. The National Cancer Institute (NCI) and the National Center for Complementary and Alternative Medicine (NCCAM) are sponsoring a number of clinical trials (research studies) at medical centers to evaluate CAM therapies for cancer.
Conventional approaches to cancer treatment have generally been studied for safety and effectiveness through a rigorous scientific process that includes clinical trials with large numbers of patients. Less is known about the safety and effectiveness of complementary and alternative methods. Few CAM therapies have undergone rigorous evaluation. A small number of CAM therapies originally considered to be purely alternative approaches are finding a place in cancer treatment—not as cures, but as complementary therapies that may help patients feel better and recover faster. One example is acupuncture. According to a panel of experts at a National Institutes of Health (NIH) Consensus Conference in November 1997, acupuncture has been found to be effective in the management of chemotherapy-associated nausea and vomiting and in controlling pain associated with surgery. In contrast, some approaches, such as the use of laetrile, have been studied and found ineffective or potentially harmful.
The NCI Best Case Series Program, which was started in 1991, is one way CAM approaches that are being used in practice are being investigated. The program is overseen by the NCI's Office of Cancer Complementary and Alternative Medicine (OCCAM). Health care professionals who offer alternative cancer therapies submit their patients' medical records and related materials to OCCAM. OCCAM conducts a critical review of the materials and develops follow-up research strategies for approaches deemed to warrant NCI-initiated research.
When considering complementary and alternative therapies, patients should ask their health care provider the following questions:
National Center for Complementary and Alternative Medicine (NCCAM)
The National Center for Complementary and Alternative Medicine (NCCAM) at the National Institutes of Health (NIH) facilitates research and evaluation of complementary and alternative practices, and provides information about a variety of approaches to health professionals and the public.
CAM on PubMed
NCCAM and the NIH National Library of Medicine (NLM) jointly developed CAM on PubMed, a free and easy-to-use search tool for finding CAM-related journal citations. As a subset of the NLM's PubMed bibliographic database, CAM on PubMed features more than 230,000 references and abstracts for CAM-related articles from scientific journals. This database also provides links to the Web sites of over 1,800 journals, allowing users to view full-text articles. (A subscription or other fee may be required to access full-text articles.) CAM on PubMed is available through the NCCAM Web site. It can also be accessed through NLM PubMed bibliographic database by selecting the "Limits" tab and choosing "Complementary Medicine" as a subset.
Office of Cancer Complementary and Alternative Medicine
The NCI Office of Cancer Complementary and Alternative Medicine (OCCAM) coordinates the activities of the NCI in the area of complementary and alternative medicine (CAM). OCCAM supports CAM cancer research and provides information about cancer-related CAM to health providers and the general public via the NCI Web site.
National Cancer Institute (NCI) Cancer Information Service
U.S. residents may call the NCI Cancer Information Service toll free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 am to 8:00 pm. A trained Cancer Information Specialist is available to answer your questions.
Food and Drug Administration
The Food and Drug Administration (FDA) regulates drugs and medical devices to ensure that they are safe and effective.
Federal Trade Commission
The Federal Trade Commission (FTC) enforces consumer protection laws. Publications available from the FTC include:
PDQ is a comprehensive cancer database available on NCI's Web site.
PDQ is the National Cancer Institute's (NCI's) comprehensive cancer information database. Most of the information contained in PDQ is available online at NCI's Web site. PDQ is provided as a service of the NCI. The NCI is part of the National Institutes of Health, the federal government's focal point for biomedical research.
PDQ contains cancer information summaries.
The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries are available in two versions. The health professional versions provide detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions provide current and accurate cancer information.
The PDQ cancer information summaries are developed by cancer experts and reviewed regularly.
Editorial Boards made up of experts in oncology and related specialties are responsible for writing and maintaining the cancer information summaries. The summaries are reviewed regularly and changes are made as new information becomes available. The date on each summary ("Date Last Modified") indicates the time of the most recent change.
PDQ also contains information on clinical trials.
A clinical trial is a study to answer a scientific question, such as whether one treatment is better than another. Trials are based on past studies and what has been learned in the laboratory. Each trial answers certain scientific questions in order to find new and better ways to help cancer patients. During treatment clinical trials, information is collected about the effects of a new treatment and how well it works. If a clinical trial shows that a new treatment is better than one currently being used, the new treatment may become "standard." Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
Listings of clinical trials are included in PDQ and are available online at NCI's Web site. Descriptions of the trials are available in health professional and patient versions. Many cancer doctors who take part in clinical trials are also listed in PDQ. For more information, call the Cancer Information Service 1-800-4-CANCER (1-800-422-6237).
Last Revised: 2011-11-15
If you want to know more about cancer and how it is treated, or if you wish to know about clinical trials for your type of cancer, you can call the NCI's Cancer Information Service at 1-800-422-6237, toll free. A trained information specialist can talk with you and answer your questions.
This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.
To learn more visit Healthwise.org
© 1995-2012 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.


text:
- Did you mean
- wooster ag facilities consisted research farm
Search results
Ohio State Report Evaluates Options for Reducing Lake Erie's Harmful Algal Blooms
Chip Tuson Several research teams, led by The Ohio State University, have concluded a three-year ... entering the lake by 40%. Now, researchers have a better understanding of what management practices need to ... be implemented, and what research still needs to be done to meet these goals by 2025. The majority of ...
News tips and events for the week of Nov. 18
Researchers with The Ohio State University College of Food, Agricultural, and Environmental Sciences (CFAES) ... November 2019 18 Converging on Wicked Systems Problems, 1–3 p.m., Nationwide & Ohio Farm Bureau 4-H ... speakers from Ohio, Iowa, and Minnesota, will explore the application of transdisciplinary research and ...
Personal Selling class learns about Woosterfest
Zimmerly (Wooster Chamber of Commerce) for visiting the BUSTEC 2232T Personal Selling class. Their insights ...
Holiday Sale
Dover Road, Wooster OH * Southeast of OARDC * Follow the signs ...
CFAES and EEOB Graduate Student Support Group
strategies Interpersonal relationships Teaching/research balance Access to other helpful resources Support ... group meetings take place on both the Columbus and Wooster campuses. Please direct all inquiries for the ... Taylor (firstname.lastname@example.com), or Program Assistant, Alicia Baca (firstname.lastname@example.com). Support group meetings in Wooster have been ...
Annual Holiday Sale
cards) Ohio State ATI Horticulture Division Flower Shop and Greenhouse 1328 Dover Road, Wooster OH * ...
News tips and events for the week of Nov. 4
feature researchers at stations around the farm for short discussions and Q&A. No registration fee for ... with China and other countries, and the impact of those relations on farmers; farm-income trends and ... (CFAES). It will be held at the Nationwide & Ohio Farm Bureau 4-H Center, 2201 Fred Taylor Drive, ...
Chow Line: How long is too long for holiday leftovers?
Sciences and its outreach and research arms, OSU Extension and the Ohio Agricultural Research and ...
Ohio State News features new study on household thermostat interactions
part on whether you're a man or a woman, new research suggests. The study has taken an initial glimpse ... conflict. The research also found that men were more likely to report their interactions with other ... battles" by Emily Caldwell featuring Sintov's research on household energy interactions. You can ...
Understand First-Generation Families to Better Support First-Generation Students
allies in providing vital support to their students. Although we know there are exceptions, research ...


text:
With all the new 1st year and 2nd year coaches at the colleges I was wondering how everyone thinks these college football teams in ND will do?
NDSU: They will win the National Title
UND: They will get a few playoff wins
U Mary: 1 win and they hire a new coach
Minot State: they will finish with 5 wins, the new coach brings good energy
Dickinson State: their tradition continues and they lose in the second round of the playoffs
Jamestown: They are moving to a new conference, 2nd year coach doesn't make the jump in wins he wants I don't see them getting more than 2 wins
Valley City State: They finish with 7 wins and just miss the playoffs
Mayville State: Their new staff shows how green they are and they gain one win, maybe
Trinity Bible: The new staff is really the old staff, they grab a few wins
Bottineau: They win 8 games, and not a single player from ND sees the field.
NDSCS: They get 1 loss.


text:
PORTERVILLE, Calif. — Three people died and four others, including two young girls, were wounded after a shooting on an Indian reservation in Central California, authorities said.
When deputies were called to a trailer Saturday night on the Tule Indian Reservation, they found the body of a man and a woman inside, Tulare County sheriff's officials said in a release Sunday. A third body was nearby.
Deputies also found a wounded male juvenile. His condition was not known.
Tulare County authorities did not immediately return a call to The Associated Press seeking details.
The Fresno Bee (http://bit.ly/WUNeOW ) reported that a vehicle with the suspect — 31-year-old Hector Celaya — and his daughters, ages 5 and 8, was pulled over by deputies early Sunday.
Celaya was then wounded during an exchange of gunfire. He was being treated for life threatening injuries, sheriff's officials said in their release.
Officials say the girls were hospitalized after they had been earlier shot by their father. One girl suffered life-threatening injuries while the other girl was less seriously hurt.
Sheriff's officials say they were able find Celaya by tracking his cellphone.
The reservation where the shooting took place is about 50 miles north of Bakersfield.
Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed


text:
Bowtrol Colon And Parasite Cleanse
You can do is that this investing brings forth realistic events which'll aid citizenries lose free weight casting pounds successfully. Likewise these should be trimming down or getting rid of all those more harmful toxins in body. So most solid foods we eat. D on Saturday and run to simply eat intellectual nourishments with colon … [Read more...]


text:
Passing motorist finds dead man in car trunk
A passer-by looking through an idling car he saw in a ditch in east Houston found a man's body in the trunk, authorities said.
The man, identified as 28-year-old Donald Michael Lapointe of Houston, had been shot at least once in the chest, and his face was swollen and cut as if he had been beaten, said Jack Harvey, a homicide investigator with the Houston Police Department.
A bag of pills was found stuffed inside his pants.
The passer-by found the body about 4 a.m. Monday at 12800 Nimitz near Normandy.
He was driving with his wife and their 4-month child when he spotted a gold, four-door car nose down in the ditch.
The car was running and the windshield wipers were on.
Harvey said the passer-by told investigators he looked through the car for something he could take. Then he grabbed the keys from the ignition to look for stereo speakers in the trunk.
When he opened the trunk he found the body.
The passer-by drove to a nearby gas station and called 911.
Harvey said the passer-by and his wife are not a suspects in the killing.
The investigator said it appeared Lapointe had been shot elsewhere, placed in the trunk, driven to the area and left where he was found.
The car has not been reported stolen.
Investigators have no suspects or motive in the shooting.


text:
Battlefield 3 Beta Drops On September 29, Open To All/
The wait is almost over! DICE has announced that the Battlefield 3 multiplayer beta will be ready and available for download on September 29. The beta is an open beta, meaning it will be open to all gamers and consoles including Xbox 360, PlayStation 3 and PC. In addition, those who pre-ordered the limited edition Medal Of Honor will be giving early access to the Battlefield 3 multiplayer beta starting September 27. Players will be given one multiplayer map when the open beta arrives called Paris: Operation Metro. This should help with the wait until Battlefield 3 hits stores on October 28. Jump past the break for the gameplay footage of what you should expect from the open beta!


text:
Neighbors send SOS on Scales Bend boat storage
JOHNSON COUNTY– One local developer has proposed a plan for an outdoor boat storage facility close to North Liberty, and the idea has taken on water with disapproving neighbors.
However, in its formal meeting of Aug. 8, the Johnson County Board of Supervisors approved the first reading of a rezoning request by Duane Kunkel of Solon that would allow him to stay on that course.
In 2011, Duane and Connie Kunkel purchased 68 acres at 2229 Scales Bend Rd., from Matthew and Brenda Conklin. The site is the previous home to the Lazy L rodeo venue and horse riding club, but Kunkel has revamped the area by installing a pond, clearing some of the foliage and demolishing the old buildings. He told the supervisors last week that his plan was to maintain the property as a rural acreage without a residence, but that he wanted to create an open boat storage rental business there in order to generate some revenue. County ordinances only allow open boat storage as a conditional use in three of the county's zoning districts; either AR (Agricultural Residential), C (Commercial) or RC (Rural Cluster).
The Kunkel property currently contains two different zoning classifications, a residual of some mass zoning actions of the 1960s: (R) Residential; and (A) Agricultural, neither of which allow for the open storage of boats that Kunkel has admittedly engaged in for the last 18 months on the property. Therefore, he sought to rezone about 12.5 acres to AR in order to proceed with a conditional use permit application to the county's Board of Adjustment.
The Johnson County Planning & Zoning Commission reviewed Kunkel's application in June, and after hearing complaints from seven neighbors in the meeting and receiving other written objections and documentation about Kunkel's activities on the property, deferred action on the application for 30 days. On July 8, the commission voted 4-0 (with one member absent) to recommend the supervisors deny approval of the rezoning request.
Still, Johnson County Planning & Zoning Assistant Director RJ Moore told the supervisors last week he felt it was an appropriate conditional use for the property in the county's immediate non-agricultural growth area, that it fit with the county's Land Use Plan, and recommended the board approve rezoning it to AR.
Complaints include reports that Kunkel has both burned and buried toxic materials on the site, ranging from building materials and old appliances to creosote-soaked telephone poles, potentially impacting the surrounding groundwater. The neighbors stated Kunkel had livestock on the property– sheep, specifically– that were chronically getting loose and roaming into the roadway, creating traffic hazards. The Johnson County Health Department was called to the site because of an outhouse that Kunkel erected on the property, essentially a shed over an open hole in the ground and reportedly about 100 feet from a neighbor's property line and drinking water source. Another neighbor complained that Kunkel had burned an old mobile home on the property, which caused significant toxic-laden fumes in the air, and had received citations from the Department of Natural Resources (DNR) and health departments in other counties where Kunkel has also developed properties.
Kunkel responded to many of the claims last week.
"We want to preserve this area at all costs," Kunkel told the supervisors. "We are putting up a fight to come up with some sort of supplemental income on this land without it going to housing."
About burning the mobile home, Kunkel said he first called the North Liberty Fire Department to inform them he would be burning the refuse, and he followed the same practices for disposal of two homes he demolished in Linn County, under the direct supervision and scrutiny of the Linn County Health Department.
"It went perfect, there were no problems at all," Kunkel said, and he had not received citations from the DNR, but simply a warning in 1999 because of soil runoff that occurred during periods of heavy rain that couldn't be remedied until the rain stopped.
Kunkel admitted building an outhouse on the Scales Bend property, but said he had since filled it in.
"Yes, I was turned in for digging a hole, and using it," he said. "We had a family reunion. Lo and behold, the health department came and said we can't use it. But in that discussion, I asked if I could just go into that timber and use it (as a bathroom), and (health department officials) said, 'Well yeah, but you shouldn't.' And then I said what about the Amish, aren't they using these things (outhouses)? And they said, 'Well yeah, but they shouldn't.' Well, somewhere along the line I stopped making that dash to the timber and went back to using (the outhouse)." That's when a neighbor came over and took photographs to document the outhouse was being used, Kunkel said. "But in eight months of using that outhouse, it filled a two-and-a-half gallon bucket. That's it. In that same area, I removed 15 to 20 loads of horse manure. Then I brought in fill dirt to cover it. That's the extent of that, and I'm paying for it." Kunkel will be required to put in a plumbed restroom if the public is allowed on the property.
Kunkel said he agreed with points made by two of his neighbors: concerns about the sight distance for vehicles pulling onto the curvy, winding road, and maintaining the quiet rural character of the area.
"That curve in the road does need to be addressed," Kunkel said. "I've had close calls myself and it should be done, regardless of what is done today." Further, Kunkel added, "It's a tranquil setting, and we want to keep it that way. I've been falling trees in that timber with a chain saw, not with a bulldozer."
Other concerns centered around potential impacts on the neighborhood should the rezoning and conditional use permit for boat storage be granted.
Tom Cannon, who lives on Scales Bend Road, pointed out Kunkel's plan includes no measures for monitoring the rental business.
"Usually when somebody does something like this, they have a house there where they can monitor what goes on," Cannon said. "He's not going to have any infrastructure, there's not going to be any security, no fencing, no gates, no lighting; it's going to be a magnet for criminal activity."
Neighbor Marge McGowen was also concerned about the potential for theft, and because the proposal has no dump station for chemicals.
"The opportunity for people to improperly dispose of waste oil, gasoline and antifreeze is there. Without any supervision, even if it's illegal on paper, it's going to happen. Vandalism will be unlimited," said McGowen. In her experience, McGowen said she had a theft from her own boat that was secured in a shed on her own property, and two thefts from a boat that was stored in a secured marina elsewhere. "With no security, this is just going to be a temptation for trouble."
Several neighbors stated they are concerned about their property values declining if a storage business is started on Kunkel's property. Scales Bend resident Dick Trimble raises thoroughbred horses on his abutting property, and he said his horses are continually spooked by the activity of dump trucks and construction vehicles next door. Mike Brotherton said an open boat storage facility can be unsightly and will change the peaceful character of the neighborhood.
Kunkel disagreed that the boat storage facility would cause problems for neighbors.
"I assure you if I think I am losing value for our property or anybody else's, it will come to a halt. I just don't see that coming; it's nothing but boat storage. It's about the most benign behavior you can get. People literally come through with their boats, roll down their windows, ask you how you're doing and they're gone with their boat. Nobody stays, nobody changes the oil in their boats. Some of these comments are bizarre."
After Kunkel and his neighbors had a chance to speak during the public hearing, the supervisors were slow to respond. Supervisor Rod Sullivan clarified to the audience that his board is only responsible for addressing the rezoning request, and that the conditional use permit required for a boat storage business was up to the county's Board of Adjustment.
Supervisor Terrence Neuzil agreed.
"Our role has nothing to do with the conditional use. The question for the supervisors is this request complaint with potential changes, and does it fit the character of the area, and that is ultimately what we are deciding up here. All the other arguments, whether you like a neighbor or not, quite frankly, that goes to the board of adjustment," said Neuzil.
Neuzil noted that should this initial rezoning request fall through, Kunkel could request to develop the property into a residential subdivision with the potential for many homes and increased traffic.
"I'm just advising you all that a no vote today leaves the potential for a significant amount of development out there," Neuzil said.
Assistant County Attorney Andy Chappell also noted that since outdoor boat storage was also a permitted conditional use in RC, Kunkel could potentially develop the property as a residential cluster development and still apply for a boat storage permit.
Supervisor Janelle Rettig posed a hypothetical question.
"So if the applicant came forward with a rural cluster application, and wanted to build between 40 and 80 homes, on 86 acres, they could also in that case go to the board of adjustment and ask for boat storage on one of the outlots, right?" she asked.
Moore confirmed that was the case.
Chappell noted while the board of supervisors does not issue conditional use permits, it could put stipulations on the use of the property to protect the area and make sure use doesn't get out of hand, such as requiring security or lighting, fencing or hours of operations, and in response to a question from supervisor John Etheredge, Moore said the permit could be revoked should those conditions be violated.
Rettig moved to approve the first reading of the rezoning request, and four the five supervisors weighed in on their decisions before the vote.
Sullivan said whether or not the rezoning was approved would not determine Kunkel's behavior as an environmental steward, and he saw the boat storage area as having the least impact on traffic and the quiet nature of the neighborhood, as opposed to a rural cluster subdivision.
Rettig said whatever mistakes had been made previously, the county health department had no current objections. She based her yes vote on individual property rights and the application's compatibility with county ordinances and the corridor land use plan.
"A property owner has private property rights, and they can do a couple things within our ordinances and regulations. We can pass the most stringent ordinances as possible, but once we've done that, landowners have right to private property right to use their land within our rules. Eighty homes is possible on this land, and I find AR to have the least impact on the neighbors," said Rettig.
Supervisor Pat Harney felt open boat storage was not an appropriate use for the area, and voted against the rezoning, as did Neuzil.
"The issue to me is opportunity, and looking at the character of the area, I think there is a better zoning possible in this area. I would like to deny this to potentially give the landowner another opportunity to look at some more opportunities available," Neuzil said.
The rezoning request passed 3-2, with the second consideration likely to appear on the supervisor's agenda for their Aug. 15 formal meeting.


text:
The 24th Philadelphia Distance Run was scheduled for Sunday September 16, 2001. Our TV crew had planned to fly east on Thursday the 13th after completing our post-production work on the inaugural Rock `n Roll Virginia Beach Half-Marathon TV show. But the events of Tuesday morning September 11th would change everything, from our travel plans, to our conception of the world through which we traveled. Yet even then running would prove an invaluable ally in the struggle to make sense of it all.
The Beatles "Yesterday" played on the Elite Racing telephone line as I waited to speak with Mike Long about our travel arrangements. The song was eerily appropriate to the mood of the nation. "…There's a shadow hanging over me," sang Paul McCartney. "Oh, yesterday came suddenly."
"The uncertainty of everything," was how Mike put it as he scrambled to reorder flights in the face of an ongoing FAA ban. "There are so many conflicting issues of security and economic impact of a flightless United States."
Philly race director Mark Stewart was scrambling, as well, feeling like he was slipping into a deep depression. There had been so many bomb threats that his secretary wouldn't come to work. He was trying to do the right thing, but not quite knowing what the 'right thing' was.
Sporting contests throughout the country had been cancelled out of respect for the national tragedy. These pseudo-battles of ours pitting mighty teams in titanic struggle upon well-groomed playing fields somehow became horribly inconsequential, if not a pure mockery of what true battles we were soon to visit. Continue reading


text:
Newsflash: Tech Executives Are Not Hurting For Cash
Tis the season to embrace your financial ruin.
It's no revelation that many of our country's top tech executives take home more money on an annual (daily?) basis than most of us will ever see in our lifetimes, but the Securities and Exchange Commission (SEC) just introduced a handy Web tool that details just how much money we're talking about.
The Executive Compensation Reader is part of new rules requiring more transparency and clarity when it comes to disclosing executive pay. The database currently has info on 500 large companies that have filed proxy statements with the SEC.
A quick perusal of the tech companies we regularly cover here at PC Magazine basically makes me want to kill myself. Uh, I mean, revel in the glory of capitalism.
Brian L. Roberts, Comcast's board chairman and CEO, for example, takes home a $2.5 yearly million salary--but with bonuses, stock awards and options, and perks, that number jumps to approximately $26 million annually.
AT&T chairman and CEO Ed Whitacre will also likely be able to fill his loved ones' stockings with iPhones, HDTVs and basically any other gadget you can think of, thanks to an annual package of approximately $60.7 million.
Carl E. Vogel, EchoStar's president, vice chairman and director, meanwhile, is practically destitute, with his paltry $2.8 million compensation package.
But what about Google?
Chairman and CEO Eric Schmidt, as well as the company's founders, Larry Page and Sergey Brin, are all in the one-dollar-salary club. The SEC documents indicate that Larry is pulling in half a million, while Larry gets $38K, and Sergey takes home $1,724, but something tells me they're not hurting for cash.
A few more depressing stats:
Alltel: Scott T. Ford, president and CEO, $14.1 million
DirecTV: Chase Carey, president and CEO, $12.4 million
Intel: Paul Otellini, president and CEO, $9.8 million
Level 3 Communications: James Q. Crowe, CEO, $8.7 million
Qwest: Richard Notebaert, chairman and CEO, $16.5 million
Sirius Satellite Radio: Mel Karmazin, CEO, $31.1 million
Sprint Nextel: Gary D. Forsee, chairman, CEO, and president, $21.3 million
Verizon: Ivan Seidenberg, chairman and CEO, $21.2 million
Ziff Davis: Chloe Albanesius, news reporter, can I borrow a dollar?


text:
Our Young Leaders Class is a respite program coupled with a unique curriculum that will introduce students to important topics such as work ethic, attitude, communication skills, time management, problem-solving, acting as a team player, self confidence, ability to accept and learn from criticism, flexibility/adaptability and working well under pressure, personal hygiene, nutrition, and how your body talks. Each class will include a recreational activity as well! The teacher for this class is Mary West, state-certified teacher degree in Special Education. Mary will use a variety of instructional techniques including video modeling, role-playing, visuals, and hands on learning to drive the content home. In addition, we will have several expert guest presenters.
WHO: Transition-aged students with any developmental disability that want to work in a community-based setting, or individuals that were previously employed with any developmental disability that want to re-enter community-based employment.
WHEN: Second and Fourth Thursdays of the month from 6pm - 8pm
WHERE: DSAW, 11709 W Cleveland Ave, Suite 2, West Allis, WI 53227.
Please contact Mary (firstname.lastname@example.com) if interested in learning about transportation options.
COST: $12.50 per hour ($25 per class). Please contact Mary (firstname.lastname@example.com) to discuss payment options, including cash, check, credit, IRIS, Family Care, and DSAW Grant.
We welcome self-advocates to join our class at any time. Please contact Mary for more details!